Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 5Recruiting 2

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 23Glioblastoma 13Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Prostatic Neoplasms 9Neoplasms 9Breast Neoplasms 9Brain Neoplasms 9Neoplasm Metastasis 8Kidney Neoplasms 8Gliosarcoma 8Melanoma 7Sarcoma 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Oligodendroglioma 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Glioma 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × temsirolimus × Clear all
NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00693433 2015-12-04

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
Plasma cell

Multiple Myeloma

NCT00483262 2013-11-11

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute

Phase 1/2 Completed
63 enrolled 11 charts
Plasma cell

Multiple Myeloma

NCT00079456 2013-10-11

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Plasma cell

Multiple Myeloma

NCT00398515 2013-09-30

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡